Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Extranodal NK/T-cell Lymphoma, Nasal Type
and you are
between 14 and 70
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%~10%. The frequency of ENKTL among NHL patients is significantly higher in Asia than in Western countries, with poor prognosis. Radiotherapy plus chemotherapy has improved the survival for these patients. But the optimal treatment schedule is controversial. The previous protocols usually contained high dose methotrexate, but the application of them is limited for the toxicity.

Provided treatments

  • Drug: Methotrexate
  • Drug: Etoposide
  • Drug: Dexamethasone
  • Drug: Pegaspargase
  • Radiation: Radiotherapy
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02631239. The sponsor of the trial is Ruijin Hospital and it is looking for 256 volunteers for the current phase.
Official trial title:
The Efficacy and Safety of Etoposide, Dexamethasone, Peg-asparaginase or Plus Methotrexate With Sandwiched Radiotherapy in the Treatment of Stage I to II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type